Novo Nordisk strikes $11bn deal to expand production of Ozempic weight loss drug

Danish drugmaker to acquire three manufacturing sites as its controlling shareholder buys US company Catalent
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×